Chronic Lymphocytic Leukemia Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Condition: Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma) Intervention: Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2022 Category: Research Source Type: clinical trials
A Study of PR2527 in Participants With Relapsed/Refractory Hematologic Malignancies
Conditions: Aggressive B-Cell Non-Hodgkin's Lymphoma; Aggressive B-Cell NHL; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma (MCL); Richter's Syndrome Intervention: Drug: PRT2527 Sponsor: Prelude Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2022 Category: Research Source Type: clinical trials
Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Condition: Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma) Intervention: Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2022 Category: Research Source Type: clinical trials
A Study of PR2527 in Participants With Relapsed/Refractory Hematologic Malignancies
Conditions: Aggressive B-Cell Non-Hodgkin's Lymphoma; Aggressive B-Cell NHL; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma (MCL); Richter's Syndrome Intervention: Drug: PRT2527 Sponsor: Prelude Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2022 Category: Research Source Type: clinical trials
Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Condition: Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma) Intervention: Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2022 Category: Research Source Type: clinical trials
A Study of PR2527 in Participants With Relapsed/Refractory Hematologic Malignancies
Conditions: Aggressive B-Cell Non-Hodgkin's Lymphoma; Aggressive B-Cell NHL; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma (MCL); Richter's Syndrome Intervention: Drug: PRT2527 Sponsor: Prelude Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2022 Category: Research Source Type: clinical trials
Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Condition: Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma) Intervention: Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2022 Category: Research Source Type: clinical trials
A Study of PR2527 in Participants With Relapsed/Refractory Hematologic Malignancies
Conditions: Aggressive B-Cell Non-Hodgkin's Lymphoma; Aggressive B-Cell NHL; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma (MCL); Richter's Syndrome Intervention: Drug: PRT2527 Sponsor: Prelude Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2022 Category: Research Source Type: clinical trials
Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Condition: Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma) Intervention: Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2022 Category: Research Source Type: clinical trials
